Pioglitazone (PIO), a thiazolidinedione (TZD) derivative, has noble mechanism of action and is a insulin sensitizer, do not increase the plasma insulin level, not cause hyperinsulinemia and hypoglycemia. It has no fatal toxicity and can be safely use in renal impairment. It can reduce the fasting plasma glucose by 25mg/dl to 50mg/dl in monotherapy. It is not lipid friendly and has tendency to produce hepatopathy. It is a costly drug. Triglitazone a analog TZD banned due to fatal hepatotoxicity and rosiglitazzone withdrawn from the market because of its toxic potentiality. Metformin (MET) is a commonly used, safe, effective, well efficacious, low cost antidiabetic agent with versatile pharmacological action and worldwide long standing experience drug. But precise mechanism of action is still unknown. It has annoying upper gastrointestinal side effect causig the potentiality noncompliance. Efficacy in reducing fasting plasma glucose 50mg/dl. Considering all these perspective the aim of this study was to find out a good efficacious, low cost, safe, tolerable insulin sensitizer which can be used both in monotherapy and combination therapy in t2dm pts.